Company news
Scynexis, Inc. news in 2023
Scynexis, Inc.'s news releases, calls and decks from 2023, newest first.
SCYNEXIS Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 12, 2023
SCYNEXIS Presents New Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Congress on Trends in Medical Mycology (TIMM)
October 23, 2023
SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Congress on Trends in Medical Mycology (TIMM) October 20-23 in Athens, Greece
October 15, 2023
SCYNEXIS Issues a Voluntary Nationwide Recall of BREXAFEMME® (ibrexafungerp tablets) due to potential for cross contamination with a non-antibacterial ß-lactam drug substance
September 26, 2023
SCYNEXIS to Participate in September Investor Conferences
August 27, 2023
SCYNEXIS Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 13, 2023
SCYNEXIS and Hansoh Pharma Announce NMPA Acceptance of the New Drug Application for Ibrexafungerp in China
July 19, 2023
SCYNEXIS Announces Achievement of First Development Milestone of $25 Million Under Exclusive License Agreement with GSK
June 20, 2023
SCYNEXIS to Participate in the Maxim Group Virtual Healthcare Conference
June 14, 2023
SCYNEXIS Reports Closing of Exclusive License Agreement with GSK for BREXAFEMME® (Ibrexafungerp Tablets)
May 11, 2023
SCYNEXIS Announces First Quarter 2023 Financial Results and Provides Corporate Update
May 10, 2023
SCYNEXIS to Present Ibrexafungerp Data at the 33rd Annual European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) April 15-18 in Denmark
April 12, 2023
SCYNEXIS Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
March 30, 2023
GSK and SCYNEXIS Announce an Exclusive Agreement to Commercialise and Further Develop Brexafemme (ibrexafungerp), a Novel, First-in-Class Medicine to Treat Fungal Infection
March 29, 2023